



THE
BLADDER CANCER
COMPANY

Photocure ASA: Transactions made under share buyback program

Oslo, Norway, 31 March 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 March 2025 of the launch of Photocure's program to repurchase up to 200,000 of its own shares for a total maximum amount of NOK 20 million during the period from 20 March 2025, until no later than the annual general meeting in 2025, pursuant to an agreement with DNB Markets.

PHO: Transactions made under share buyback program

For the period from and including 19 March 2025, through 28 March 2025, the Company purchased a total of 179,648 shares at an average price of NOK 57.57 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

Date	Aggregated daily volume (#shares)	Weighted average share price per day (NOK)	Total daily transaction value (NOK)
20.03.2025	26 492	57.42	1 519 695
21.03.2025	27 143	56.51	1 536 700
24.03.2025	27 113	56.85	1 542 420
25.03.2025	26 945	58.87	1 577 298
26.03.2025	28 276	58.10	1 645 615
27.03.2025	22 574	57.65	1 303 154
28.03.2025	21 105	57.70	1 217 760
Accumulated under the program	179 648	57.57	10 342 644

The issuer's holding of own shares:

Following the completion of the above transactions, Photocure owns a total of 493,796 of own shares (including 314,148 shares owned prior to the launch of the buyback program), corresponding to 1.08% of Photocure's share capital.

Appendix:

An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact:

Erik Dahl

CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com and www.cysview.com. All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is made public by Photocure ASA pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.